Summer 2027

Quality Data Science Co-op

MD Q&C Digital Solutions

Posted on 8/31/2026

Deadline 9/14/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$23.50 - $52.50/hr

No H1B Sponsorship

Cincinnati, OH, USA

Hybrid

Hybrid work is required in Cincinnati.

Bachelor's, Master's

Category
Data & Analytics (1)
Required Skills
Microsoft Office
Python
Data Science
R
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Be enrolled in an accredited college or university and pursuing a Bachelor's or Master's degree in Mechanical Engineering, Biomedical Engineering, Chemical Engineering, Electrical Engineering, Computer Engineering, Software Engineering, or a related field.
  • Be in the second year or above of school at the beginning of the co-op term in January 2027 and have a graduation date after April 2027.
  • Have a cumulative GPA of 3.0 or above.
  • Be authorized to work in the United States for the full duration of the co-op from January 2027 through April 2027.
  • Have familiarity with basic statistics concepts and terminology.
  • Be detail-oriented, highly organized, and able to manage multiple tasks.
  • Demonstrate the ability to work independently and as part of a team.
  • Be proficient with Microsoft Office, including Word, Excel, and PowerPoint, and have strong oral and written communication skills.
  • Be permanently authorized to work in the United States and not require employment visa sponsorship, including H-1B or green card sponsorship, at the time of application or in the future.
Responsibilities
  • Collaborate with internal and external teams supporting advanced analytics to implement customer-centric solutions for data analytics and process improvements.
  • Perform software development and validation to support medical device quality system digital solutions.
  • Learn and apply software development and lifecycle management techniques.
  • Promote digital culture and capabilities across Johnson & Johnson medical devices.
  • Work with a diverse team of data scientists, analytics application developers, quality engineers, and related professionals.
  • Meet with Quality management to discuss risks and opportunities for respective projects.
  • Support Ethicon, Inc. in Cincinnati, Ohio.
  • Work on a team assigned to one of the various franchises of the respective company.
  • Report to the MD Q&C Digital Solutions Advanced Analytics Manager and receive project assignments.
  • Participate in and/or lead on-campus activities such as learning committees, volunteer events, and meet-and-greet luncheons with full-time associates.
Desired Qualifications
  • Demonstrated leadership or participation in campus programs and/or community service activities.
  • Previous quality-related experience.
  • Knowledge of Food and Drug Administration or regulatory guidance.
  • Medical-related experience, such as a previous co-op at a medical device company or work or volunteer experience at a hospital.
  • Programming experience, such as R or Python, and data analytics experience.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved IMAAVY for wAIHA on August 24, 2026, opening a new market.
  • Q2 2026 sales reached $25.3 billion, and J&J raised 2026 outlook to $101.1 billion.
  • TECVAYLI plus DARZALEX won FDA approval in March 2026 and strong July 2026 data.

What critics are saying

  • The July 2026 talc deal needs 95% claimant acceptance, or litigation continues.
  • UK talc claims filed in October 2025 remain outside the U.S. settlement.
  • STELARA biosimilar erosion keeps hitting sales while TREMFYA must replace it fast.

What makes Johnson & Johnson unique

  • J&J spans pharmaceuticals and MedTech, reducing dependence on any single franchise.
  • TREMFYA, DARZALEX, and RYBREVANT create multiple billion-dollar growth engines.
  • Management targets oncology leadership and $50 billion oncology sales by 2030.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.

Yahoo Finance
Aug 26th, 2026
J&J eyes $50B oncology target by 2030 as 96% of portfolio grows 14%

Johnson & Johnson's stock upside is being underestimated as investors focus narrowly on STELARA's patent cliff, according to a new analysis. The drug now represents just 4% of the Innovative Medicine portfolio, whilst the remaining 96% is growing at over 14%. The company operates 28 different billion-dollar platforms, demonstrating diversification beyond single-product dependency. Under baseline assumptions—revenue compounding at 6.8% annually, net margin improving from 22% to 24%, and P/E multiple compressing from 31.3x to 26.6x—the analysis projects upside over three years. If net margin returns to its three-year average of 29%, upside could expand further. The most significant drag comes from multiple compression; holding the P/E flat at current levels would lift total upside to 35%. Management's goal to become the leading oncology company by 2030, targeting over $50 billion in oncology sales, could reshape the growth profile.

Yahoo Finance
Aug 26th, 2026
J&J wins first anemia drug approval but stock slips 1% as investors eye commercial hurdles

Johnson & Johnson has secured the first FDA approval for a treatment specifically targeting warm autoimmune hemolytic anemia, a rare and potentially deadly blood disorder. The drug, Imaavy, can now treat steroid-exposed adults and patients aged 12 or older. In clinical trials involving 115 adults, patients receiving Imaavy were approximately three times more likely than those on placebo to achieve sustained haemoglobin improvement after 24 weeks. The treatment also produced an average haemoglobin increase of one gramme per decilitre after the first week. Despite the regulatory milestone, J&J shares fell roughly 1% to $270.665 on Wednesday. The company generated $25.3 billion in second-quarter sales and raised its annual revenue midpoint to $101.1 billion, making this single indication unlikely to significantly impact near-term results.

Yahoo Finance
Aug 25th, 2026
Louisiana jury awards $10M in talc case, J&J liable for $1.2M amid broader settlement talks

A Louisiana jury awarded $10 million in a mesothelioma case linked to talc exposure, assigning Johnson & Johnson over $1.2 million of the liability. The jury found J&J's talc products unreasonably dangerous and inadequately labelled regarding asbestos risks. The verdict is one of multiple talc trial losses for Johnson & Johnson alongside a proposed $5.5 billion settlement aimed at resolving approximately 76,000 ovarian cancer claims. If the settlement proceeds with sufficient claimant participation, it could reduce legal uncertainty. Despite the legal challenges, Johnson & Johnson reported record quarterly sales supporting its Innovative Medicine and MedTech divisions. The company's narrative projects $120.5 billion revenue and $28.6 billion earnings by 2029, requiring 7.2% yearly revenue growth. Ongoing talc verdicts and potential follow-on cases continue to shape perceptions of the company's legal risk alongside its expanding medicines and MedTech portfolio.

PR Newswire
Aug 24th, 2026
FDA approves IMAAVY as first-ever treatment for warm autoimmune hemolytic anemia

The US Food and Drug Administration has approved IMAAVY (nipocalimab-aahu) as the first treatment specifically for warm autoimmune hemolytic anemia in adults and children aged 12 and older. Johnson & Johnson announced the approval following FDA Priority Review. wAIHA is a rare, life-threatening condition where autoantibodies destroy red blood cells, causing severe anaemia and fatigue. Previously, only corticosteroids and immunosuppressants were available. The approval is based on the Phase 2/3 ENERGY study. Results showed approximately three times as many patients receiving IMAAVY achieved durable haemoglobin levels versus placebo by 24 weeks. Patients demonstrated a mean haemoglobin increase of 1 g/dL at Week 1. IMAAVY is an immunoselective FcRn blocker designed to reduce pathogenic IgG autoantibodies whilst preserving B-cell function. Common side effects included peripheral oedema, diarrhoea, and fever.